Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension

Figures & data

Figure 1 Mean intraocular pressure ± standard deviation of total population across visits (n = 47).

Note: *P < 0.001, week 12 vs week 0 (baseline).

Figure 2 Mean intraocular pressure ± standard deviation of prostaglandin analog therapy groups across visits (n = 47).

Notes: ^†P < 0.05, week 12 vs week 0 (baseline); *P < 0.001, week 12 vs week 0 (baseline).

Table 1 Patient demographics (n = 47)

Demographics	n (%)
Age (years)
≤55	8 (17)
56–65	15 (32)
66–75	16 (34)
≥76	8 (17)
Gender
Male	16 (34)
Female	31 (66)
Race
Caucasian	47 (100)
Qualified eye(s)
OU	43 (91)
OD	3 (6)
OS	1 (2)
Diagnosis
Primary open-angle glaucoma	44 (94)
Ocular hypertension	3 (6)
Prostaglandin analog therapy
Latanoprost 0.005%	20 (43)
Travoprost 0.004%	20 (43)
Bimatoprost 0.03%	4 (9)
Tafluprost 0.0015%	3 (6)

Figure 3 Symptom-free frequency at baseline and week 12 (n = 47).

Table 2 Adverse events related to brinzolamide-timolol (n = 10)

Adverse event	n
Bitter taste	3
Burning eye	3
Blurred vision	2
Dry eye	1
Glued eye	1